Branch² Intelligence

Granules India expecting sole first to file status on Ruxolitinib Extended-Release Tablets

IN · 2026-10-07

India — direction and magnitude withheld

Direction and magnitude are withheld for India-region stories. Named companies below are shown without any directional call or impact magnitude; the omission is deliberate, not missing data. This intelligence is provided for informational purposes only. Branch² is not a SEBI-registered research analyst. This is not investment advice. Past performance is not indicative of future results. Please consult a SEBI-registered investment adviser before making any investment decision. Users must comply with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Key takeaway

Granules India files Paragraph IV ANDA for generic Jakafi (ruxolitinib ER), claiming sole first-to-file status for 180-day US exclusivity

  1. Step 1 · The triggerGranules India submits Paragraph IV ANDA for ruxolitinib ER, claiming sole first-to-file status with the US FDA
  2. Step 2 · Knock-onFDA review and patent litigation determine whether Granules wins 180-day generic exclusivity or shares/competes at commodity launch
  3. Step 3 · Knock-ona confirmed sole FTF triggers commercial manufacturing scale-up at Granules' Indian facilities, pulling demand through the domestic supplier chain
  4. Step 4 · Knock-onIndian SME suppliers of API intermediates and excipients see order-book inflection, but only if litigation does not block launch
  5. Step 5 · Reaches youthe SME supplier's own working-capital cycle stretches if it builds inventory ahead of an uncertain FDA/litigation timeline, compressing cash conversion

The trigger is reported by the source below. The steps that follow are Branch²’s traced reasoning — how the shock could reach a business like yours, not a prediction.

Source: The Hindu BusinessLine

See what today’s news does to your business. Atri by Branch² — Early-warning intelligence for your business

This is automated analysis for information only. It is not investment advice, not a recommendation, and not a solicitation to buy or sell any security. Branch² is not authorised or regulated. Do your own research.